The world's largest manufacturer of healthcare products, Johnson & Johnson, is making India a global hub of its research and development as it looks to ramp up its pharmaceutical business in the country.
The increasing number of generic players tapping the US market for known molecules has resulted in pricing pressures and lean margins.
D Aravindakshan was the managing director of Kerala State Drugs and Pharmaceuticals at Alleppey for many years before taking over as the head of Agastya Biopharma
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
The Bangalore-based Himalaya Herbal Healthcare has struck strategic alliances with leading retail chains in its main export markets such as the US, Singapore and Malaysia.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
A recent court ruling in the US on allowing the declaratory judgment provision in the US patent law has come as a boost to Indian pharmaceutical companies such as Ranbaxy, Dr Reddy's, Sun Pharma and Lupin.
In a fresh round of patent battle over the launch of generic drugs in the US market, domestic pharmaceutical majors Orchid, Sun Pharma and Ranbaxy Laboratories have been sued by Cima Labs, Otsuka Pharmaceutical Co and Abbott Laboratories, respectivel
Fortis Healthcare, promoted by the Singh family of Ranbaxy, plans to expand its network to 40 hospitals within three years by either acquiring new facilities or setting up greenfield projects
Beer is gaining more popularity in some of the non-traditional beer markets in North India like Rajasthan, Punjab, Delhi and Uttar Pradesh.
Amgen, the world's largest biotechnology company, has entered India by opening a wholly owned subsidiary Amgen Technology in Mumbai.
Mumbai-based Advanced Enzyme Technologies Ltd, the largest manufacturer of enzymes in the country, will invest Rs 115 crore to set up three biotech production facilities.
With the bidding for the generics business of Merck set to begin from Monday, domestic pharmaceutical companies in the fray, Ranbaxy Laboratories and Dr Reddy's Laboratories, are unlikely to go for an all-out bidding war.
Spectrum Retail Mart, a retail chain of medical stores and fast moving consumer goods, has set up shop in Mumbai with an initial investment of over Rs 90 crore (Rs 900 million).
After being raided by Federal officials, Ranbaxy Laboratories Ltd, India's largest pharmaceutical company, has been taken to court in the US by a consumer health group that supports the sale of low-priced generic medicines.
The Indian company that acquires Merck Generics, the multinational drug maker's generics (non-patented) business, up for sale, will be able to compete against the top global players
Mumbai-based pharmaceutical company Indoco Remedies Ltd plans to tap the regulated markets of Europe and the US.
In Mumbai, Reliance Health Venture has already acquired the Mandke hospital, which will be converted into a 650-bed super specialty hospital with six divisions.
As many as 15 companies across the world have lined up generic variants of Pfizer's Zoloft (Sertaline HCL), for which the exclusive six-month marketing period granted to the successful patent challenger, Teva of Israel, ends on Tuesday.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances